Literature DB >> 9657776

c-kit activating mutations and mast cell proliferation in human leukemia.

A Beghini, L Larizza, R Cairoli, E Morra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9657776

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Authors:  Zhifu Xiang; Frederike Kreisel; Jennifer Cain; AnnaLynn Colson; Michael H Tomasson
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

2.  Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Authors:  Joseph D Growney; Jennifer J Clark; Jennifer Adelsperger; Richard Stone; Doriano Fabbro; James D Griffin; D Gary Gilliland
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

3.  Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation.

Authors:  Hamza Celik; Cates Mallaney; Alok Kothari; Elizabeth L Ostrander; Elizabeth Eultgen; Andrew Martens; Christopher A Miller; Jasreet Hundal; Jeffery M Klco; Grant A Challen
Journal:  Blood       Date:  2015-01-22       Impact factor: 22.113

4.  Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Authors:  Magda Bahcall; Taebo Sim; Cloud P Paweletz; Jyoti D Patel; Ryan S Alden; Yanan Kuang; Adrian G Sacher; Nam Doo Kim; Christine A Lydon; Mark M Awad; Michael T Jaklitsch; Lynette M Sholl; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

5.  Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling.

Authors:  P V Spirin; T D Lebedev; N N Orlova; A S Gornostaeva; M M Prokofjeva; N A Nikitenko; S E Dmitriev; A A Buzdin; N M Borisov; A M Aliper; A V Garazha; P M Rubtsov; C Stocking; V S Prassolov
Journal:  Leukemia       Date:  2014-04-14       Impact factor: 11.528

6.  Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo.

Authors:  Chie Nishioka; Takayuki Ikezoe; Jing Yang; Atsushi Miwa; Taizo Tasaka; Yoshio Kuwayama; Kazuto Togitani; H Phillip Koeffler; Akihito Yokoyama
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

Review 7.  STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells.

Authors:  Hein Schepers; Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  JAKSTAT       Date:  2012-01-01

8.  TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.

Authors:  Sebastian Drube; Franziska Weber; Christiane Göpfert; Romy Loschinski; Mandy Rothe; Franziska Boelke; Michaela A Diamanti; Tobias Löhn; Julia Ruth; Dagmar Schütz; Norman Häfner; Florian R Greten; Ralf Stumm; Karin Hartmann; Oliver H Krämer; Anne Dudeck; Thomas Kamradt
Journal:  Oncotarget       Date:  2015-10-06

9.  A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).

Authors:  Sebastian Huss; Helen Künstlinger; Eva Wardelmann; Michaela A Kleine; Elke Binot; Sabine Merkelbach-Bruse; Thomas Rüdiger; Jens Mittler; Wolfgang Hartmann; Reinhard Büttner; Hans-Ulrich Schildhaus
Journal:  Mod Pathol       Date:  2013-04-19       Impact factor: 7.842

10.  Altered trafficking of mutated growth factor receptors and their associated molecules: implication for human cancers.

Authors:  Shunsuke Kon; Nobuhide Kobayashi; Masanobu Satake
Journal:  Cell Logist       Date:  2014-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.